POSIFLEX-TECHNOLOGY
Posiflex Technology, Inc. , a global leader in Point of Sale (POS), self-service kiosks, and embedded computing technologies. Posiflex has been focused on product applications of retail market trends and endeavors to improve users’ operational efficiency with cutting edge technology since its foundation in 1984. Posiflex is honored to receive the Taiwan Excellence Award 2021 for its innovative all-in-one Android POS, HS-3314A .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005001/en/
The Ministry of Economic Affairs Taiwan established the Taiwan Excellence Awards in 1993. Eligible candidates are subjected to cover four major aspects of “R&D”, “Design”, “Quality” and “Marketing” to identify outstanding products that offer “Innovative Value” while being “made in Taiwan”. Products that have been selected for the Taiwan Excellence Awards would serve as examples of the domestic industries and be promoted by the government internationally to shape the creative image for Taiwanese businesses.
The HS-3314A series is a 14” Android 9.0 PCAP touch POS system with a built-in printer and designed with the high-performance Rockchip RK3399 platform and various peripherals. Built with unique innovation and a compact body, HS-3314A is equipped with a high-speed, detachable thermal receipt printer. Its innovative screwless and modular design not only makes installation simple and maintenance easy but also allows for a variety of peripherals including a secondary display, MSR, fingerprint sensor, and barcode scanner. The whole system greatly improves retailer operation and work efficiency with space-saving design and reduced downtime.
Not only has Posiflex been building the best POS systems for the retail industry, but it is also in sync with the rapid rise of self-service technology. As the world has been deeply affected by the COVID-19 outbreak, it has unleashed a demand for safety-conscious products such as self-service kiosks. Posiflex introduces the new Mercury EK Series to its sophisticated self-service solutions to help operators succeed with the rising need for the self-service kiosk. Built to be compact and functional, the Mercury EK Series is available in 15” PCAP touch screen in landscape mode while 15.6” & 21.5” touch screens are available in both landscape and portrait mode. Designed with flexibility in mind, the Mercury EK Series can deploy as either countertop or floor-standing as well as customizable with peripherals including NFC/RFID reader, fingerprint sensor, 2D scanner, status indicator, and an EMV payment device. The versatility of the Mercury EK Series allows retailers to customize as their businesses need. They are also engineered for single-user assembly and ease of maintenance, thus reducing costs of deployment and service. With all the flexibility and user-friendly features, the Mercury EK Series can serve as an extension of employees, handling mundane tasks while allowing employees to focus on providing better customer service, therefore creating more demand and business for retailers.
With the award-winning all-in-one POS HS-3314A and the small-footprint kiosk Mercury EK Series, Posiflex provides POS/Kiosk solutions with variety and quality for the retail industry to meet customers’ various demands as well as create exceptional consumer experiences.
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell , further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom